Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

K. Suzuki, K. Sunami, K. Ohashi, S. Iida, T. Mori, H. Handa, K. Matsue, M. Miyoshi, E. Bleickardt, M. Matsumoto, M. Taniwaki

Research output: Contribution to journalLetterpeer-review

8 Citations (Scopus)
Original languageEnglish
Article numbere540
JournalBlood cancer journal
Volume7
Issue number3
DOIs
Publication statusPublished - 2017 Mar 10

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this